MOTS-c Regulatory Status in 2026

Where a widely discussed mitochondrial peptide actually stands with regulators.

TL;DR

MOTS-c regulatory status in 2026: this mitochondrial-derived peptide is not FDA-approved. FDA removed MOTS-c from Category 2 on April 22, 2026, as one of 12 peptides whose nominations were withdrawn. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding it to the list. The committee is advisory, and FDA has not made a final decision.

MOTS-c regulatory status: is MOTS-c FDA approved?

MOTS-c is not FDA-approved for any use, including metabolic support or exercise performance. It was discovered inside mitochondrial DNA (in plain English: the small separate set of genetic instructions living inside a cell's energy-producing structures) and has mostly been studied in mice and small early human trials. No pharmaceutical company has taken it through the FDA approval process for a specific medical indication.

Is MOTS-c legal in 2026?

MOTS-c occupies a regulatory gray zone. Researching it is not illegal. FDA removed MOTS-c from Category 2 on April 22, 2026, after its nomination was withdrawn (FDA, Bulk Drug Substances Nominated for Compounding). As of September 14, 2026, MOTS-c is not in any FDA 503A category and is not on the 503A bulks list. FDA uses Category 2 for bulk substances that raise significant safety risks.

Why is MOTS-c still Category 2?

It is not. On April 22, 2026, FDA removed 12 peptides from Category 2 after their nominations were withdrawn. MOTS-c was one of them, along with BPC-157 and TB-500. In an April 16, 2026 notice in the Federal Register, FDA had already scheduled a Pharmacy Compounding Advisory Committee meeting (Federal Register, FDA agency notices). At its July 23–24, 2026 meeting, the committee voted to recommend adding MOTS-c to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

Who asks about MOTS-c's regulatory status

People come to this question after reading about MOTS-c in exercise-science or longevity circles and wanting to know if a physician can actually prescribe it. Regulatory status for Category 2 peptides has shifted multiple times in the past year, so a compound's story today may not match what a forum post from six months ago said.

The Halftime POV

We state the regulatory facts plainly, however popular a peptide is online. MOTS-c's science is genuinely interesting. Its regulatory status is genuinely unresolved. We track FDA and HHS notices closely so our guidance reflects where things stand today, not where they might land eventually.

Related reading:

• MOTS-c: The Mitochondria-Derived Peptide Explained
• Who Asks About MOTS-c and What They Want to Understand
• Why Some Peptides Are Still Category 2
• Category 1 vs Category 2 Explained

FAQ

Is MOTS-c FDA approved? No. MOTS-c is not FDA-approved as a drug for any use. It is studied in animal and early human research on metabolism and exercise physiology, not an approved medication.

Is MOTS-c legal in 2026? MOTS-c is not illegal to research. FDA removed MOTS-c from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, MOTS-c is not in any FDA 503A category and is not on the 503A bulks list.

Is MOTS-c still Category 2? No. MOTS-c was one of 12 peptides FDA removed from Category 2 on April 22, 2026, along with BPC-157 and TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-c to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

What is MOTS-c studied for? MOTS-c is a mitochondrial-derived peptide, encoded in mitochondrial DNA. Early research links it to metabolic regulation and exercise-related signaling, mostly in animal models.

Disclaimer

Several peptides discussed in this article — including MOTS-c — were previously in FDA's Category 2. FDA removed them from Category 2 on April 22, 2026. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

Sources

• U.S. Food and Drug Administration, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
• Federal Register, U.S. Food and Drug Administration agency notices: https://www.federalregister.gov/agencies/food-and-drug-administration
• National Center for Biotechnology Information, PubMed search: MOTS-c mitochondrial-derived peptide: https://pubmed.ncbi.nlm.nih.gov/?term=MOTS-c+mitochondrial+derived+peptide